AquaLiv Technologies Subsidiary AquaLiv, Inc. Discusses Registration In Kenya Concerning Its HIV/AIDS Treatment
SEATTLE, Oct. 31, 2011 /PRNewswire/ -- AquaLiv Technologies (OTCBB: AQLV) subsidiary, AquaLiv, Inc., discusses alternative medicine registration in Kenya for their NatuRx™ HIV/AIDS treatment.
The company previously announced that Kenyan officials recommend they register NatuRx™ HIV/AIDS as an alternative medicine treatment and that approval could be granted within 30-60 days.
"The process isn't quite as simple as it was explained to us," stated AquaLiv CEO, Craig Hoffman. "It isn't just the treatment that is being registered. Registration also requires completed retail packaging and inspection of a manufacturing facility that complies with cGMP (Current Good Manufacturing Practices) regulation. We wanted to simply get approval for the treatment, but that just isn't possible without the manufacturing component in place."
Mr. Hoffman continued, "We are looking for a manufacturing partner that could eventually supply the treatment to all African countries and we have identified some candidates in both Kenya and India. The big question for us right now is do we sign on with a partner capable of manufacturing our treatment as a liquid solution, as we do now in our laboratory, or should we wait until we have modified the treatment to be delivered in tablet form. We're closer than ever to being able to deliver all NatuRx™ treatments in tablet form and we think we will know definitively before the end of our planned clinical trial, which is when we would actually begin sales of the product."
The company further explained that tablets are more economical to distribute and will require fewer manufacturing partners overall.
"We're confident we will have the manufacturing issues worked out before the end of the trial," added Bill Wright, CEO of AquaLiv Technologies. "However, we communicated to our investors that an alternative medicine registration could be granted around this time and felt it was important to give investors an update."
Based on AquaLiv's patented BioT™ Bioinformation Technology, NatuRx™ formulations utilize novel wave-based information composites in lieu of molecules for treatment.
For more information about AquaLiv, visit their website: http://www.aqualiv.net
About AquaLiv Technologies, Inc.:
AquaLiv Technologies, Inc., through its subsidiaries, offers unique solutions and applications for a variety of industries and emerging technologies.
AquaLiv, Inc. is a life sciences research and development company creating novel products for numerous industries. The company's patented technology alters the behavior of organisms, including plants and humans, without chemical interaction. From increased crop yields to drug-free medicine, AquaLiv is providing innovative, ingredient-free solutions to the world's largest problems. To learn more about AquaLiv, please visit: www.aqualiv.net.
Safe Harbor: Statements contained in this news release, other than those identifying historical facts, constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and the Safe Harbor provisions as contained in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relating to the Company's future expectations, including but not limited to revenues and earnings, technology efficacy, strategies and plans, are subject to safe harbors protection. Actual Company results and performance may be materially different from any future results, performance, strategies, plans, or achievements that may be expressed or implied by any such forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements.
AquaLiv Technologies, Inc.
SOURCE AquaLiv Technologies, Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.